2016
The Role of the Immune System in Ovarian Cancer and Implications on Therapy
Menderes G, Schwab CL, Black J, Santin AD. The Role of the Immune System in Ovarian Cancer and Implications on Therapy. Expert Review Of Clinical Immunology 2016, 12: 681-695. PMID: 26821930, DOI: 10.1586/1744666x.2016.1147957.Peer-Reviewed Original ResearchConceptsOvarian cancerImmune systemGoal of immunotherapyConventional cytotoxic chemotherapyCause of deathAdvanced surgical techniquesDifferent immunotherapiesTremendous toxicityCytotoxic chemotherapyGynecologic malignanciesDisease recurrenceMicroscopic diseaseTreatment optionsImmune modulationSurgical techniqueCurrent evidenceDisease pathogenesisCurrent ongoing studiesCancerImmunotherapyRecurrenceOngoing studiesChemotherapyMalignancyPathogenesis
2015
Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients
Bellone S, Centritto F, Black J, Schwab C, English D, Cocco E, Lopez S, Bonazzoli E, Predolini F, Ferrari F, Silasi DA, Ratner E, Azodi M, Schwartz PE, Santin AD. Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients. Gynecologic Oncology 2015, 138: 11-17. PMID: 25931171, PMCID: PMC4469551, DOI: 10.1016/j.ygyno.2015.04.027.Peer-Reviewed Original ResearchConceptsCytotoxic T lymphocytesCancer patientsPole tumorsT cellsHigher IFN-γ expressionLevels of CD8Endometrial cancer patientsTumor-specific CD4T cell responsesEndometrial cancer cellsIFN-γ expressionHelper armCTL responsesEndometrial cancerFavorable prognosisBetter prognosisEndometrial carcinomaLymphoid subsetsNaïve CD4T lymphocytesTumor extractsCD4CD8Immune systemCell responses
2014
Past, present and future targets for immunotherapy in ovarian cancer
Schwab CL, English DP, Roque DM, Pasternak M, Santin AD. Past, present and future targets for immunotherapy in ovarian cancer. Immunotherapy 2014, 6: 1279-1293. PMID: 25524384, PMCID: PMC4312614, DOI: 10.2217/imt.14.90.Peer-Reviewed Original ResearchConceptsOvarian cancerImmune systemGoal of immunotherapyOvarian cancer immunotherapyConventional cytotoxic chemotherapyCause of deathAdvanced surgical techniquesDifferent immunotherapiesTremendous toxicityCytotoxic chemotherapyGynecologic malignanciesDisease recurrenceMicroscopic diseaseCancer immunotherapyImmune modulationSurgical techniqueCurrent evidenceImmunotherapyCurrent ongoing studiesCancerRecurrenceOngoing studiesFuture targetsChemotherapyMalignancy
2005
Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy.
Santin AD, Bellone S, Roman JJ, Burnett A, Cannon MJ, Pecorelli S. Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy. Current Pharmaceutical Design 2005, 11: 3485-500. PMID: 16248803, DOI: 10.2174/138161205774414565.Peer-Reviewed Original ResearchConceptsCervical cancer patientsT cell responsesDendritic cellsCervical cancerCancer patientsE7 oncoproteinsLate-stage cervical cancer patientsTumor-specific T-cell responsesImmune systemCell responsesPowerful antigen-presenting cellsDendritic cell-based immunotherapyPrimary T cell responsesCell-mediated immune responsesAutologous dendritic cellsTherapeutic HPV vaccinesTreatment-induced immunosuppressionPrimary radiation therapyHuman papillomavirus infectionAdvanced cervical cancerCell-based immunotherapyTumor-specific target antigensAntigen-presenting cellsImportant risk factorGold standard treatment
2000
Lymph node metastases
Santin A. Lymph node metastases. Cancer 2000, 88: 175-179. PMID: 10618621, DOI: 10.1002/(sici)1097-0142(20000101)88:1<175::aid-cncr24>3.0.co;2-f.Peer-Reviewed Original ResearchConceptsRegional lymph nodesSecondary lymphoid organsLymph nodesImmune systemCancer patientsLymphoid organsT cellsUninvolved regional lymph nodesTumor cellsTumor-bearing hostsNaive T cellsHost immune systemT cell activationNovel immunotherapeutic toolsActive immunotherapyImmunotherapy protocolsDendritic cellsHematogenous disseminationRLN dissectionSurgical removalImmunotherapeutic toolRadical dissectionClinical trialsAnatomic barriersTumor antigens
1998
Routine Lymph Node Dissection in the Treatment of Early Stage Cancer:Are We Doing the Right Thing?
Santin A, Parham G. Routine Lymph Node Dissection in the Treatment of Early Stage Cancer:Are We Doing the Right Thing? Gynecologic Oncology 1998, 68: 1-3. PMID: 9454650, DOI: 10.1006/gyno.1997.4900.Peer-Reviewed Original ResearchConceptsLymph node dissectionNode dissectionLymph nodesProphylactic lymph node dissectionRoutine lymph node dissectionRegional lymph nodesRecent immunological studiesTreatment of patientsEarly-stage solid tumorsEarly-stage cancerEarly-stage malignanciesManagement of cancerElective lymphadenectomyTherapeutic dissectionAntitumor reactivitySalvage rateBloc resectionSurgical interventionPrimary tumorRegional nodesStage cancerLymphatic pathwaysMatter of controversySolid tumorsImmune system